

# Index

- acamprosate 135  
 ACC *see* anterior cingulate cortex (ACC)  
 acute mania 15–20, 41, 44, 77, 80, 165, 169, 184 *see also* mania  
   clinical subtypes of patients with 10  
   diagnostic criteria for 11  
   dosing and duration of treatment for 11–12  
   emergency management of 35  
   lithium, use of 88  
   monotherapy for treatment of 36  
   non-pharmacological treatment of 13  
   pharmacological treatment of 13, 35–6, 75  
   recommendations for 33, 36  
   psychotherapeutic treatment of 205  
   quality of life enjoyment and satisfaction questionnaire 170  
   substance-abuse issues, impact of 185  
   treatment algorithm for 14, 36, 37  
 ADHD *see* attention deficit hyperactivity disorder (ADHD)  
 adjunctive lamotrigine  
   for BD type I depression treatment 25  
   for second-line treatment of bipolar depression 39  
 adjunctive quetiapine 41  
   for BD type I depression treatment 26  
 adolescent-onset bipolar disorder 73–4  
 adulthood, bipolar disorder in 73 *see also* late-life bipolar disorder  
   care during transition to young adulthood 80  
   clinical features 84–7  
   depression 77  
   management of 87–90  
 aetiopathogenesis, of bipolar disorder 9  
 AF *see* amniotic fluid (AF)  
 age of onset and clinical features, of late-life bipolar disorder 84–5  
 akathisia 18, 19, 110  
 alcohol-use disorders 122, 129, 130, 132  
   alcohol abuse and 133  
   bipolar patients with co-morbid 134  
   bipolar women with 131  
 Alzheimer's disease 86  
 American Academy of Pediatrics 100, 116  
 American Association of Clinical Endocrinologists 114, 123  
 American Board of Psychiatry and Neurology 191  
 American Diabetes Association (ADA) 114  
 American Psychiatric Association (APA) 33, 113, 114, 115, 145, 181, 196  
 amisulpride 13, 37, 109, 115  
   and antimanic treatment 19  
 amniotic fluid (AF) 99  
 anhedonia 66, 68  
 anterior cingulate cortex (ACC) 67  
 anticonvulsants 78, 113–14  
   carbamazepine 16–17  
   lamotrigine 109  
   for late-life BD treatment 88–9  
   other anticonvulsants with potential antimanic properties 17  
   sodium valproate 109  
   valproate 17  
 antidepressants 4, 36, 62, 142  
   for BD type I depression treatment 26–7  
   for BD type II depression treatment 28–9  
   for late-life BD treatment 89–90  
   for rapid cycling BD treatment 29  
   tricyclic 99, 145  
 antidiabetic medications 107  
 antimanic  
   agents 15, 20, 35, 36, 146  
   medication 11, 19, 35  
 antipsychotics 4, 15, 35, 95, 108, 114–15  
   and extrapyramidal side effects 110  
   for late-life BD treatment 89  
   therapy 113, 114  
 antisocial personality disorder 129, 131  
 anxiety disorders 1, 7, 9, 44, 50, 73, 74, 123, 124, 131, 142, 146, 147, 169  
   common symptom of 120  
   co-morbid 94, 120, 121, 122, 126, 131, 132, 185  
   implications of BD associated with co-morbid 120  
   personality disorders and 131  
   pharmacotherapy for treatment of 125  
   recommended scales for assessing 188  
 APA *see* American Psychiatric Association (APA)  
 aripiprazole 78, 79, 134  
   for antimanic treatment 17–18  
   for BD type I depression treatment 27–8, 41  
 asenapine 13  
   for antimanic treatment 19, 35  
 assertive outreach (AO) teams 175, 182  
 atherosclerosis 125  
 attention deficit hyperactivity disorder (ADHD) 74, 101, 123  
 atypical antipsychotics 15, 26, 109–10, 125  
   amisulpride 19  
   aripiprazole 17–18  
   asenapine 19  
   olanzapine 18  
   quetiapine 18  
   risperidone 18–19  
   ziprasidone 19  
 Axis I disorders 69, 94, 120, 129, 139, 203  
 Axis II disorders 48, 69, 120  
 BAI *see* Beck anxiety inventory (BAI)  
 Barcelona Bipolar Disorders Program 45, 59  
 Bauer collaborative care model 182  
 BDI *see* Beck depression inventory (BDI)  
 BDNF *see* brain-derived neurotrophic factor (BDNF)  
 Beck anxiety inventory (BAI) 188–9  
 Beck depression inventory (BDI) 68, 122, 205  
 Beck's cognitive model of mania 45

## Index

- behavioural reward system (BRS) 68  
 behavioural rhythms 152  
 benzodiazepines 88  
   for antimanic treatment 20  
   for co-morbid SUD treatment 134  
   for improving sleep quality 157  
   as mood stabilisers 77  
 bimodal distribution of age of illness 84  
 binge-eating disorder 108, 142  
 binging-purging anorexia 142  
 bipolar depressive symptoms 38–40  
 bipolar disorder (BD) *see also*  
   *individual entries*  
   care and stress upon family 80  
   clinical trials on efficacy and safety of  
     drugs for 134  
   continuous circular 93  
   diagnostic issues in treatment of  
     adolescent-onset bipolar disorder  
       73–4  
     manic-like symptoms in pre-  
       adolescent children 74  
   effect of co-morbid substance-use  
     disorders on outcome in 132–3  
   episodes 176  
   imaging studies of 123–4  
   impact on psychosocial functioning  
     and quality of life 9  
   interrelatedness of respect, rapport  
     and recovery 5–6  
   maintenance treatment of  
     clinical management and practical  
       considerations 41–2  
     prophylaxis 40  
     role of psychosocial treatments  
       and 40–1  
   management of 1, 80–1  
     diagnosis 33–4  
     goals of treatment 34  
     treatment guidelines for 33  
   metabolic state in 106–8  
   non-adherence to medication, issue  
     of 3  
   overview of 9  
   physical consequences of 201  
   with psychotic features 1  
   rates of recurrence of 131–2  
   recovery, personal medicine and  
     treatment for 1–2  
   resource issues for 80  
   review of psychoeducation studies  
     for 47–9  
   screening for 34  
   summary of comparative studies for  
     53–4  
   symptoms for 2  
   treatment for  
     pharmacological 134–5  
     psychotherapy 135–6  
     young people 80  
   types of *see* bipolar disorder (BD)  
     type I; bipolar disorder (BD) type  
       II  
   bipolar disorder (BD) type I 9, 15, 120,  
     130, 143, 165, 181, 204  
   illness in women 93  
   interpersonal and social rhythm  
     therapy trials for 52  
   mood episode 51  
   pharmacotherapy  
     adjunctive lamotrigine 25  
     adjunctive quetiapine 26  
     antidepressants 26–7  
     aripiprazole 27–8  
     carbamazepine 25  
     ethyl-eicosapentaenoic acid (EPA)  
       27  
     lamotrigine 24–5  
     lithium 24  
     mifepristone 27  
     modafinil 27  
     olanzapine/fluoxetine  
       combination (OFC) 26  
     pramipexole 27  
     quetiapine 25–6  
     valproate 25  
   QoL in 171  
   weight changes in patients 110  
 bipolar disorder (BD) type II 9, 120,  
   143, 166, 181  
 bipolar illness in women with 93  
 cyclothymia and 144  
 pharmacotherapy  
   antidepressants 28–9  
   pramipexole 28  
   quetiapine 28  
 QoL in 171  
 bipolar disorder patients  
   obesity and unhealthy dietary habits  
     in 123  
   QoL of 171  
   response to electroconvulsive  
     therapy 62–3  
 Bipolar Disorders Program 45, 59, 178  
 bipolar mood symptoms 51  
 bipolar spectrum disorders 130, 134,  
   139, 142, 187, 200  
 bipolar women  
   bipolar illness in  
     childhood abuse 94  
   co-morbid anxiety disorder and  
     94  
   course of 93–4  
   diagnostic delay 94  
   suicidality in 94  
   management of reproductive health  
     issues in  
     breastfeeding 100  
     contraception 97–9  
     general and sexual health care 97  
     hyperprolactinaemia 95  
     hypothalamo-pituitary-gonadal  
       axis dysfunction 94  
     polycystic ovary syndrome 95–7  
     pregnancy and puerperium  
       99–100  
     pre-pregnancy planning 99  
     prolactin-elevating medication 96  
   menstrual abnormalities in 95  
   mood symptoms in 93  
   panic disorder and social phobia 94  
   psychological and psychosocial  
     issues for  
       development of self-identity in  
       bipolar adolescent girl 101  
       mothers with bipolar disorder  
       101–2  
       self-identity and relationship  
       issues in adults 101  
   rapid-cycling disorder in 94  
 blood-brain barrier 17, 19, 100  
 Body Mass Index (BMI) 42, 106, 107,  
   111, 114  
 borderline personality disorder (BPD)  
   68, 139, 141, 184, 185  
   co-morbid conditions for 121  
   correlation with mood  
     disorders 143  
   impact of 120  
   relation with bipolar spectrum  
     disorders 142  
   sub-affective personality disorders  
     and 143  
 brain cells 64  
 brain imaging in bipolar disorder  
   imaging for  
     diagnostic purposes 195–6  
     prognostic reasons 196  
   imaging techniques and findings  
     194–5  
 brain-derived neurotrophic factor  
   (BDNF) 124  
 breast cancer 6, 95  
 breastfeeding 99, 100, 117  
 bronchial carcinoma 95  
 BRS *see* Behavioural reward system  
   (BRS)  
 bulimia 68, 96, 142  
 Bunney–Hamburg scale 25  
 bupropion 27, 29, 38, 40, 145  
  
 California verbal learning test 204  
 Canadian Network for Mood and  
   Anxiety Treatments (CANMAT)  
   33, 34, 36–9, 181

## Index

- recommendations for maintenance treatment of BD 41
- cannabis 130, 133, 142
- carbamazepine 19, 115
  - as anticonvulsants 109
  - for antimanic treatment 16–17
  - for BD type I and type II depression treatment 25
  - for late-life BD treatment 89
- cardiac rhythm abnormalities 89
- cardiovascular diseases (CVDs) 106, 111, 121
  - European guidelines for prevention of 112
  - relationship with bipolar disorder 107
  - and sudden death 123
- cardiovascular pathophysiology 124
- care and stress upon family, in early stages of illness 80
- catatonia 12, 62
  - electroconvulsive therapy for 64
- CBF *see* cerebral blood flow (CBF)
- CBT *see* cognitive behavioural therapy (CBT)
- central nervous system disorders 135
- cerebellar atrophy 17
- cerebral blood flow (CBF) 65, 67
- CGI *see* clinical global impression (CGI)
- CGI-S *see* clinical global impression–severity scale (CGI-S)
- childhood abuse 94
- children and adolescents 95, 122–3
  - characteristics of BD in 142
  - family-focused therapy for 51
  - management of physical health issues in 117
  - pharmacotherapy of acute mania in 75
  - prevalence of BD in 73
- chlorpromazine 13, 16, 36, 63
  - for antimanic treatment 20
- cingulate gyrus 66–7, 194
- circadian and sleep/wake processes
  - circadian instability in aetiology of BD 152–3
  - management of circadian and sleep/wake rhythms 154
  - sleep management in bipolar disorder
    - assessment of sleep disturbances 157
    - common sleep disturbances 156–7
    - improvement of sleep quality 157–60
- social zeitgeber hypothesis and social rhythm management 154–6
  - therapeutic process 153–4
- circadian rhythms 45, 54, 152–5, 160
- citicoline 135
- clinical global impression as modified for bipolar illness (CGI-BP) depression 27
- clinical global impression (CGI) 188
- clinical global impression–severity scale (CGI-S) 26, 170
- clinical practice, assessment scales for 186–7
- clozapine 13, 14, 19, 36, 41, 100, 109, 110, 112, 114, 115, 117
  - for rapid cycling BD treatment 29
- cocaine abuse 73, 130, 131, 134, 135, 141, 185
- cognitive behavioural therapy (CBT) 16, 45–6, 53, 155–6, 164, 186, 205
  - Lam's programme for 46
  - review of trials 49–50
  - summary of trials 50–1
- cognitive functioning tests 203–4
- cognitive impairments, in euthymic bipolar patients 201
- cognitive remediation (CR) 206
- cognitive skills, affect of bipolar disorder on 200
- collaborative care (CC) 53
  - model for management of BD 177–9
  - RCTs for bipolar disorder 178
- co-morbid anxiety disorders 94, 120, 121, 126, 147, 185
  - in children and adolescents 122–3
- co-morbid diabetes mellitus 123
- co-morbid organic (neurological) disorders 16, 74
- co-morbid SUD
  - benzodiazepine for treatment of 134
  - clinical features of bipolar patients with 134
  - lifetime prevalence rates of 129
  - rates in clinical samples of bipolar patients 130
- co-morbidity
  - alcoholism 133
  - between BD and SUDs 131
  - bipolar disorder associated with
    - 120–1
    - anxiety disorders 121
    - cardiovascular disease and sudden death 123
    - children and adolescents 122–3
    - diabetes 123
    - medical conditions 123
- metabolic syndrome 123
  - studies after 2005 121–2
  - treatment 125
- pathogenesis of 131–2
- pathophysiological significance of anxiety 124
- bipolar disorder 123–4
- blood pressure variability 125
- cardiovascular pathophysiology 124
- heart rate variability 124
- hypothalamic–pituitary–adrenal (HPA) axis 124
- respiratory irregularity 125
- psychiatric 131
- rates in clinical samples of patients diagnosed with SUDs 131
- service-delivery terms in management of 176
- with substance abuse 132–3
- with SUDs 130, 132
- computerised tomography (CT) 194
- Confidential Enquiries into Maternal Deaths (CEMD) 94
- congenital malformations (CMs) 99
- contraception 97–9
- coronary artery diseases 107, 121
- corticotrophin-releasing factor (CRF) 124
- CR *see* cognitive remediation (CR)
- CRF *see* corticotrophin-releasing factor (CRF)
- CRHTT *see* crisis resolution and home treatment team (CRHTT)
- crisis management (CM) 51, 56
- crisis resolution and home treatment team (CRHTT) 180
- CT *see* computerised tomography (CT)
- cyclothymia
  - BD type II depressions and 144
  - bipolar nature of 139
  - bipolar spectrum disorders and 142
  - characteristics of 139
  - and co-morbid obsessive–compulsive disorder 147
  - course of 143–4
  - cyclothymic–irritable temperament 143
  - drug abuse and 141
  - eating disorders and 142
  - epidemiological and clinical aspects 140–1
  - impulse-control disorders in 142
  - intensity of mood swings 140

## Index

- obsessive-compulsive symptoms  
   in 142  
 panic attacks 142  
 practical management of 148  
 psychiatric co-morbidity 141–3  
 psychological aspects of 141  
 reasons for difficulties in  
   treating 145  
 social anxiety and 142  
 treatment strategies and practical  
   management 144–7  
 cytochrome P450 enzyme 19
- ‘daily mood charts’ for BD 186
- deep brain stimulation (DBS)  
   anatomical correlates of brain reward  
   system as targets for 67–8  
   cingulate gyrus as target for 66–7  
   inferior thalamic peduncle 68–9  
   in psychiatric conditions 66
- dementia 85, 86, 89, 90, 196
- depression 9, 33  
   adjunctive therapy for 39  
   electroconvulsive therapy in  
     treatment of 62–3  
   management of 37–8  
     clinical 39–40  
     pharmacological treatment 38–9  
   mortality rates 24  
   neurobiological models of 66  
   psychosocial impairment 24  
   symptoms 38  
   treatment algorithm for  
     management of 39  
   treatment of 77  
   unipolar 184, 194
- depressive psychosis 94
- dexamethasone suppression test (DST)  
   124, 200, 206
- dextroamphetamine sulphate 68
- diabetes mellitus 89, 95, 97, 106, 107,  
   109, 123
- Diagnostic and Statistical Manual of  
   Mental Disorders* 10, 74
- diffusion MRI tractography 67
- disinhibition syndrome 86
- divalproex 25, 26, 35  
   for bipolar depression treatment 39  
   for rapid cycling BD treatment 29
- dopaminergic (D<sub>2</sub>) hypothalamic  
   neurons 95
- double-blind placebo-controlled  
   (DBPC) studies, of mood-  
   stabilising pharmacotherapy 75
- drug abuse 129, 130, 141, 142, 144, 146
- drug–drug interactions 88, 114
- DST *see* dexamethasone suppression  
   test (DST)
- dual mania 10
- dysphoric mania 15
- ECA *see* Epidemiologic Catchment  
   Area (ECA)
- ECT *see* electroconvulsive therapy  
   (ECT)
- EE *see* expressed emotion (EE)
- egosyntonic hypomania 145
- elderly patients  
   medications and other modalities in  
     treatment of mania 16  
   suffering from bipolar disorder 117
- electroconvulsive therapy (ECT) 15, 87  
   for antimanic treatment 20, 63  
   for bipolar depression treatment 40,  
     62–3  
   for catatonia treatment 64  
   continuation and maintenance in  
     treatment-resistant BD 64  
   efficacy and safety in depressive  
     illness 62  
   for mania treatment 63  
   in mixed affective states 63–4  
   for treatment of severe mania or  
     depression during pregnancy 116  
   treatment-resistant BD 64
- EMBLEM *see* European mania in  
   bipolar longitudinal evaluation of  
   medication (EMBLEM)
- emotional instability 101, 141, 142, 148
- endometrial carcinoma 94
- end-organ dysfunction 199
- Enhanced Relapse Prevention (ERP)  
   programme 181
- Epidemiologic Catchment Area (ECA)  
   129
- epileptiform seizures 17
- EPSs *see* extrapyramidal side effects  
   (EPSs)
- ethyl-eicosapentaenoic acid (EPA) 38  
   and BD type I depression treatment  
   27
- euphoric mania 15, 16, 18
- European mania in bipolar longitudinal  
   evaluation of medication  
   (EMBLEM) 10, 18
- expressed emotion (EE) 46
- extrapyramidal side effects (EPSs) 18,  
   19, 78, 110, 117
- extrapyramidal symptoms 110
- familial pure depressive disease  
   (FPDD) 67
- family and school supports, for bipolar  
   disorder patients 80
- family-focused therapy (FFT) 46–7, 79,  
   80, 156, 170, 186, 205  
   for adolescents 51  
   modules of 47  
   trials  
     review of 51  
     summary of 51–2
- FAST *see* functioning assessment short  
   test (FAST) scale
- FBC *see* full blood count (FBC)
- F-fluoro-deoxyglucose (FDG) 67
- FFT *see* family-focused therapy (FFT)
- fMRI *see* functional magnetic  
   resonance imaging (fMRI)
- FPDD *see* familial pure depressive  
   disease (FPDD)
- Framingham stroke risk score 86
- fronto-temporal dementia (FTD) 85
- full blood count (FBC) 100, 112, 113
- functional magnetic resonance imaging  
   (fMRI) 67, 123, 195, 201, 206
- functioning assessment short test  
   (FAST) scale 171, 190
- gabapentin 41, 125, 146, 147  
   for late-life BD treatment 89  
   for treatment of acute mania 36
- GAD *see* generalised anxiety disorder  
   (GAD)
- GAF *see* global assessment of  
   functioning (GAF)
- generalised anxiety disorder (GAD) 1,  
   120, 121, 122, 131, 188
- generic community mental health  
   teams 180
- global assessment of functioning  
   (GAF) scale 122, 132, 166, 189–90
- globus pallidus 68
- glucocorticoid receptors (GR) 27, 107,  
   200
- HADS *see* hospital anxiety and  
   depression scale (HADS)
- haloperidol 13, 15, 17, 18, 35, 36, 63, 89,  
   165, 169, 170  
   and antimanic treatment 19–20
- Hamilton depression rating (HAM-D)  
   *see* Hamilton depression rating  
   scale (HDRS)
- Hamilton depression rating scale  
   (HDRS) 27, 29, 62, 68, 78, 122,  
   187–8, 204
- health care system 184  
   general and sexual 97

## Index

- health issues, associated with bipolar disorder  
 anticonvulsants 109  
 antipsychotic drugs and  
 extrapyramidal side effects 110  
 atypical antipsychotics 109–10  
 management of 111–13  
 medications 108  
 mood stabilisers 108–9  
 special populations 115–17  
 treatment-specific monitoring 113–15  
 weight gain 110  
 health-related quality of life (HRQOL) 163  
 hormones  
 affect on moods 199–200  
 replacement therapy 93, 97  
 hospital anxiety and depression scale (HADS) 189  
 HPA *see* hypothalamic-pituitary-adrenal (HPA) axis  
 HPT *see* hypothalamic-pituitary-thyroid (HPT)  
 HRQOL *see* health-related quality of life (HRQOL)  
 hypercortisolism 206  
 hyperlipidaemia 79, 89, 95, 97  
 hyperphagia 34  
 hyperprolactinaemia 19, 95, 96, 97, 109, 110, 114, 115, 117  
 hypersomnia 34, 139, 143, 156, 157  
 hypertension 95, 106, 107, 109, 111, 121, 123, 125  
 hypnotics 141  
 hypogonadotrophic hypogonadism 96  
 hypomania 9, 16, 63, 139, 184  
 antidepressant-induced 143  
 episode 140  
 symptoms of 131  
 hypothalamic-pituitary-adrenal (HPA) axis 106, 124, 199  
 hypothalamic-pituitary-thyroid (HPT) 106  
 hypothalamo-pituitary-gonadal axis dysfunction 94  
 ICM *see* intensive clinical management (ICM)  
 IDS *see* inventory of depressive symptomatology (IDS)  
 IFIT *see* integrated family and individual therapy (IFIT)  
 index depressive episode 41, 144  
 inferior thalamic peduncle, for patient with TRD 66, 68–9  
 inositol 25  
 insomnia 66, 156, 158  
 cognitive behavioural therapy for 157  
 integrated family and individual therapy (IFIT) 51, 57  
 integrated group therapy 135  
 intensive clinical management (ICM) 57, 155  
 vs. interpersonal and social rhythm therapy 52  
*International Classification of Diseases* 10  
 International Society of Bipolar Disorders 184  
 interpersonal and social rhythm therapy (IPSRT) 40, 47, 51, 155, 156, 186, 205  
 vs. intensive clinical management (ICM) 52  
 phases of 48  
 for treatment of bipolar disorder 52  
 trials  
 review of 52  
 summary of 52–3  
 interpersonal therapy (IPT) 47, 79, 80  
 inventory of depressive symptomatology (IDS) 27  
 IPSRT *see* interpersonal and social rhythm therapy (IPSRT)  
 IPT *see* interpersonal therapy (IPT)  
 lamotrigine 26, 36, 76, 77, 98, 99, 100, 110, 113, 114, 116, 134  
 adverse effects in young people 78–9  
 as anticonvulsants 109  
 antidepressant properties 146  
 for antimanic treatment 17, 75  
 for BD type I depression treatment 24–5  
 breastfeeding, use during 117  
 for late-life BD treatment 89  
 monotherapy 24–5, 38, 40, 41  
 for rapid cycling BD treatment 29, 148  
 for treatment of adult bipolar depression 77, 109  
 late-life bipolar disorder  
 clinical features of  
 age of onset 84–5  
 illness course and outcome 85  
 neuroimaging studies and vascular disease 86–7  
 secondary mania and neurological co-morbidity 85–6  
 management of 87–90  
 levetiracetam 13, 17, 37  
 LFT *see* liver function tests (LFT)  
 LIFE *see* longitudinal interval follow-up evaluation (LIFE)  
 Life Goals Program 45, 49, 59, 178  
 lithium 13, 17, 18, 19, 26, 35, 36, 39, 44, 63, 76, 113, 129  
 adverse effects in young people 78–9  
 antidepressant properties 146  
 for antimanic treatment 16, 77  
 for bipolar depression treatment 24, 40, 77  
 clinics 179–80  
 for late-life BD treatment 88  
 management of physical health issues associated with 113  
 medications during breastfeeding 117  
 monotherapy 42  
 as mood stabilisers 108–9  
 for patients with mixed episodes 37  
 for pharmacotherapy of acute mania 75  
 for prophylaxis bipolar disorder treatment 41  
 for rapid cycling BD treatment 29  
 safe use in older people 87  
 teratogenic potential of 98  
 for treating acute bipolar depression 40  
 lithium–haloperidol combination pharmacotherapy 63  
 liver function tests (LFT) 112, 113, 185  
 longitudinal interval follow-up evaluation (LIFE) 49, 50, 53  
 lorazepam 13, 18, 20, 35, 88  
 MADRS *see* Montgomery–Asberg depression rating scale (MADRS)  
 magnetic resonance diffusion tensor imaging 194  
 magnetic resonance imaging (MRI) 194–5  
 major depression (MD) 10, 66, 84, 122, 147, 200, 206  
 core behavioural symptom of 68  
 major depressive disorder (MDD) 106, 121, 124  
 mania 9, 129 *see also individual entries*  
 Beck's cognitive model of 45  
 camphor-induced seizures in treatment of 62  
 clinical management of 36–7  
 diagnostic criteria for 11  
 dosing and duration of treatment 11–12  
 electroconvulsive therapy in treatment of 63  
 emergency management of acute 35



## Index

- frequency of symptoms 12  
 medications and other modalities in treatment of  
   anticonvulsants 16–17  
   atypical antipsychotics 17–19  
   experimental medications 20  
   lithium 16  
   typical neuroleptics 19–20  
 monotherapy and skilful polypharmacy for treatment of 12–15  
 pharmacological and non-pharmacological treatments 13  
 pharmacological treatment of acute 35–6, 75  
   recommendations for 36  
 principles for treatment of 10–11  
 psychotic symptoms 37  
 secondary mania and neurological co-morbidity 85–6  
 subtype and severity of 15–16  
 symptoms of 131, 134  
 treatment algorithm 14, 37  
 types of 10  
 manic-depressive illness 139  
 MAOIs *see* monoamine oxidase inhibitors (MAOIs)  
 Mattis dementia rating scale 85  
 MBS *see* metabolic syndrome (MBS)  
 MCID *see* minimal clinically important difference (MCID)  
 MDD *see* major depressive disorder (MDD)  
 MDQ *see* mood disorders questionnaire (MDQ)  
 medications  
   antidiabetic 107  
   antihypertensive 95  
   antipsychotic 35, 36, 95, 114, 116, 117, 125, 206  
   combination 26, 35, 36, 146  
   evidence-based 186  
   health issues in bipolar disorders 108  
   prophylactic 63, 100, 115  
   psychotropic 17, 87, 94, 117, 124, 204  
   for treatment of mania 35  
 memory loss 63, 199  
 menstrual cycle dysfunction 94  
 mental health services 102, 136, 176, 181  
 metabolic disorders 106  
 metabolic syndrome (MBS) 106, 121, 123  
   NCEP ATP III criteria for 107  
   pathophysiology of 108  
 mifepristone 29  
   for BD type I depression treatment 27  
 Milkowitz's family treatment programme, for bipolar disorder 46  
 minimal clinically important difference (MCID) 170  
 mini-mental state examination (MMSE) 85  
 modafinil, for BD type I depression treatment 27  
 monoamine oxidase inhibitors (MAOIs) 147  
 Montgomery–Asberg depression rating scale (MADRS) 25, 26, 27, 28, 68, 122, 188  
 'Mood chart' self-monitoring 78  
 mood disorders, affect of hormone on 199–200  
 mood disorders questionnaire (MDQ) 33, 187  
 mood stabilisers 4, 36, 40, 77, 89, 117, 145, 148  
   agents as 20, 77  
   lithium 108–9  
   teratogenic potential of 98  
   therapy 125  
 MRI *see* magnetic resonance imaging (MRI)  
 MSIF *see* multidimensional scale for independent functioning (MSIF)  
 multidimensional scale for independent functioning (MSIF) 164  
 naltrexone 134, 135  
 National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) 106, 123  
 National Comorbidity Survey (NCS) 120, 129, 130  
 National Comorbidity Survey Replication (NCS-R) 129, 130  
 National Epidemiologic Survey on Alcohol and Related Conditions 122, 130  
 National Health Service 64  
 National Institute for Health and Clinical Excellence (NICE) 113, 115, 116  
 NCS *see* National Comorbidity Survey (NCS)  
 NCS-R *see* National Comorbidity Survey Replication (NCS-R)  
 neurocognitive impairment 85, 87, 200, 201, 202  
 neurodegenerative disorders 201  
 neurodevelopmental disorders 77  
 neuroleptic malignant syndrome 76, 78  
 neuroleptics 15  
   benzodiazepines 20  
   chlorpromazine 20  
   haloperidol 19–20  
 North American Association for the Study of Obesity 114  
 obsessive-compulsive disorder (OCD) 120, 121, 122, 124, 131, 147, 185  
 obsessive-compulsive symptoms 76, 142, 144, 147  
 OCD *see* obsessive-compulsive disorder (OCD)  
 OCPs *see* oral contraceptive pills (OCPs)  
 oestrogen therapy 93  
 olanzapine 110, 125, 169  
   for antimanic treatment 18  
   for BD type I depression treatment 26  
 olanzapine/fluoxetine combination (OFC) 26, 40  
 oral contraceptive pills (OCPs) 115  
 oral contraceptives (OCs) 78, 96, 99, 113, 115  
 oxcarbazepine, for antimanic treatment 17  
 paediatric bipolar disorder 74  
 panic attacks 142, 146  
 panic disorder (PD) 94, 120, 121, 122, 142, 146, 147, 185  
 Parkinsonism 89  
 paroxetine 25, 26, 27, 99, 100, 125, 147  
 pathological altruism 141  
 PD *see* panic disorder (PD)  
 personal medicine (PM)  
   categories, subtypes and unique features of 2  
   concept of 1–2  
   Deegan's cascading effect of 5  
   defined 2  
   discussion with patients to avoid non-adherence to 3  
   dual functionality of 2  
   interplay and treatment adherence 2–3  
   and removing barriers to treatment and medication adherence 3–4  
   self-perpetuating reinforcement phenomenon of alignment 4–5  
   types of 3  
 personality disorders (PDs) 48, 55, 94, 120, 131, 139, 141–5, 148, 184, 185  
 PET *see* positron emission tomography (PET)

## Index

- pharmacological management, of bipolar disorder 35–40
- pharmacotherapy *see also specific medications*
- of acute mania 75
- adverse effects in young people 78–9
- and choice of initial agent 75–7
- for enhancing medication adherence 79
- evidence and guiding symptoms for 76
- evidence-based treatment 75
- for maintenance mood stabilisers 77–8
- maintenance therapy 77–8
- for medical and mood monitoring 78
- recommendations for bipolar disorder 41
- for treatment of
- BD type I depression 24–8, 77
- BD type II depression 28–9, 77
- rapid cycling BD 29
- phenytoin 13, 37, 41
- for antimanic treatment 17
- phospholipid metabolism 135
- Pittsburgh sleep quality index (PSQI) 157
- pituitary cells 95
- placebo adjunctive therapy 38, 41
- placebo-controlled monotherapy 18, 25, 26
- PM *see* personal medicine (PM)
- polycystic ovary syndrome (PCOS) 17, 95–7, 109, 116
- polydipsia 78, 79, 88
- positron emission tomography (PET) 68, 195
- post-traumatic stress disorder (PTSD) 121, 122, 124, 125, 131
- pramipexole
- for BD type I depression treatment 27
- for BD type II depression treatment 27, 28
- pregabalin 17
- pregnancy in women, with bipolar disorder 115–16
- prophylaxis bipolar disorder
- index depressive episode 41
- pharmacological treatment for 41
- protein kinase C inhibition 20
- PSQI *see* Pittsburgh sleep quality index (PSQI)
- psychiatric disorders 6, 44, 62, 73, 97, 120, 132, 134, 157, 168, 190
- psychiatric medications 3, 7
- Deegan's cascading effect of 5
- self-perpetuating reinforcement phenomenon of alignment 5
- psychiatric syndromes 66
- psychoeducation 44–5, 54
- review of 47–9
- Psychological Treatment of Bipolar Disorder* (Johnson and Leahy) 165
- psychosocial treatments, impact on cognitive outcome in bipolar patients 205
- psychotherapy, evidence-based 79–80
- psychotic mania 1, 10, 15, 18, 19, 76
- PTSD *see* post-traumatic stress disorder (PTSD)
- puerperal psychosis 94
- QALY *see* quality-adjusted life year (QALY)
- quality of life enjoyment and satisfaction questionnaire (Q-LES-Q) 169, 170, 190
- quality of life (QoL) 187
- assessment of 163
- in bipolar disorder 166–8
- abnormal mood states 169
- degree of impairment 168–9
- development of disorder-specific scale 171
- treatment outcome 169–71
- impact of treatment interventions on 189
- in patients with schizophrenia 169
- psychosocial functioning and 162
- incorporating into clinical practice 171–2
- QoL in bipolar disorder 166–71
- rationale for assessing 164–5
- psychosocial functioning for use in clinical practice 171–2
- quality-adjusted life year (QALY) 196
- quetiapine 125
- for antimanic treatment 18
- for BD type I depression treatment 25–6
- for BD type II depression treatment 25–6, 28
- for rapid cycling BD treatment 29
- randomised controlled trials (RCTs) 15, 16, 18, 26, 33, 44, 46, 47, 49–53, 62, 63, 88, 109, 114, 129, 144, 146, 175, 183
- rapid cycling BD 74, 77, 122, 125, 132, 143
- pharmacotherapy for 29
- in women 93
- rapid mood fluctuations 142
- RCTs *see* randomised controlled trials (RCTs)
- resting energy expenditure (REE) 108
- retigabine 13, 17
- reversible inhibitors of monoamine oxidase (type A) (RIMAs) 147
- risperidone 77
- and antimanic treatment 18–19
- as mood stabiliser 25
- SADS-C *see* schedule for affective disorders and schizophrenia (SADS-C)
- scales for assessing symptoms and severity of bipolar disorder
- Hamilton depression rating scale 187–8
- Montgomery–Asberg depression rating scale 188
- Young mania rating scale 188
- schedule for affective disorders and schizophrenia (SADS-C) 51
- schizophrenia 15, 20, 26, 27, 46, 73, 144, 164, 180, 184
- SCN *see* suprachiasmatic nucleus (SCN)
- secondary mania and neurological co-morbidity 85–6
- sedating antipsychotics 157
- sedatives 141
- selective serotonin reuptake inhibitor (SSRI) monotherapy 29, 38, 39, 40, 145
- self-care strategies, for personal medicine 2
- self-management strategies, in bipolar disorder 164
- self-medication, for bipolar disorder 132
- serotonin-norepinephrine reuptake inhibitors (SNRIs) 145
- serum electrolytes 112
- service delivery for bipolar disorder
- assessment of key ingredients of 177
- models for
- assertive outreach teams 182
- collaborative care model 177–9
- determining implementation for service change 182–3
- early intervention teams 182
- extended role of lithium clinic 179–80
- interface with primary care 181–2
- specialist affective disorder 180
- supporting generic community mental health teams 180–1

## Index

- reasons for 175–6
- universal needs of patients 176–7
- severe mood and behavioural dysregulation (SMD) 74
- sex steroids 93
- sexual dysfunction 95, 96, 115, 145
- sexually transmitted disease 97
- SFBN *see* Stanley Foundation Bipolar Network (SFBN)
- single photon emission computed tomography 195
- sleep disturbances, assessment of 157
- sleep quality, cognitive-behavioural strategies for improving 158–9
- sleep/wake cycle 16, 152, 154
- SMD *see* severe mood and behavioural dysregulation (SMD)
- SNRIs *see* serotonin-norepinephrine reuptake inhibitors (SNRIs)
- social anxiety 142, 147
- social rhythm metric (SRM) 47, 48, 156
- social rhythm therapy (SRT) 79, 80, 155, 170, 186
- social rhythms 47
  - chronic instability in 156
- social zeitgeber hypothesis and social rhythm management 154–6
- sodium valproate 17, 98, 109, 125
- somatic anxiety symptoms 188
- specialist affective disorder services 180
- specialist mood disorder services 180
- SRM *see* social rhythm metric (SRM)
- SRT *see* social rhythm therapy (SRT)
- SSRI monotherapy *see* selective serotonin reuptake inhibitor (SSRI) monotherapy
- Stanley Foundation Bipolar Network (SFBN) 122, 130, 131, 163
- STEP-BD *see* Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
- Stevens–Johnson syndrome 40, 100, 109
- structural brain imaging, in bipolar disorder 194
- substance-abuse treatment programme 135
- substance-use disorders (SUD) 130, 176
  - effect of bipolar disorder on 129, 133
- substance-use treatment services 136
- subsyndromal mania 11
- SUD *see* substance-use disorders (SUD)
- suprachiasmatic nucleus (SCN) 152
- systematic care management program 49
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) 25, 27, 53, 123, 130, 134, 169
- tardive dyskinesia 19, 20, 76, 78, 87, 89, 110, 117
- TAU *see* treatment as usual (TAU)
- TCAs *see* tricyclic antidepressants (TCAs)
- temperament and character inventory (TCI) 132
- Texas Medication Algorithm Project (TMAP) 48, 49, 175
- theoretical models, for bipolar disorder
  - cognitive behavioural therapy 45–6, 49–51
  - family-focused therapy 46–7, 51–2
  - interpersonal and social rhythm therapy 47
  - psychoeducation 44–5, 49
  - thyroid dysfunction 16, 76, 108, 199
  - thyroxine, for rapid cycling BD treatment 29
- tiagabine 17, 36
- TMAP *see* Texas Medication Algorithm Project (TMAP)
- TMS *see* transcranial magnetic stimulation (TMS)
- topiramate 17, 36, 38, 41, 75–9, 77, 99, 135
- toxic epidermal necrolysis 109
- training and assessment tools, for diagnosis of bipolar disorder
  - assessment of symptoms and severity of bipolar disorder
  - Hamilton depression rating scale 187
  - Montgomery–Asberg depression rating scale 188
  - assessment scales for clinical practice 186–7
  - Beck anxiety inventory 188–9
  - clinical global impression 188
  - common training/skill problems encountered by clinicians
  - clarification of ‘personality’ issues 185
  - diagnosis of bipolar disorder 184–5
  - identification of co-morbid anxiety disorders 185
  - identification of substance-abuse issues 185
- side effects and adherence with treatment 185–6
- functioning assessment short test 190
- global assessment of functioning 189–90
- hospital anxiety and depression scale 189
- mood disorders questionnaire 187
- psychosocial functioning and quality of life 189
- quality of life enjoyment and satisfaction questionnaire 190
- training in BD diagnosis, treatment and rating scales
  - basic clinical exposure 190
  - education for maintenance of competence in professional societies 191
  - key tools–rating scales and diagnostic instruments 190–1
  - Young mania rating scale 188
- training in BD diagnosis, treatment and rating scales
  - basic clinical exposure 190
  - education for maintenance of competence in professional societies 191
  - key tools–rating scales and diagnostic instruments 190–1
- transcranial magnetic stimulation (TMS) 64–5
  - in depressed patients with unipolar and bipolar course 65
- transcranial stimulation, in bipolar disorder 9, 64–5
- TRD *see* treatment-resistant depression (TRD)
- treatment as usual (TAU) 49, 50, 56, 177
- treatment for bipolar disorder
  - pharmacological 134–5
  - psychotherapy 135–6
  - young people 80
- treatment-resistant depression (TRD) 66, 67, 125
- tricyclic antidepressants (TCAs) 38, 99, 125, 145, 147
- typical mania 10
- unipolar depression 10, 28, 33, 47, 50, 62, 63, 84, 94, 106, 120, 142, 144, 153, 156, 166, 177, 181, 184, 194–6, 199
- vagus nerve stimulation
  - antidepressant effect of 66
  - for bipolar disorder 65–6



Cambridge University Press  
978-0-521-73489-9 - Practical Management of Bipolar Disorder  
Edited by Allan H. Young, I. Nicol Ferrier and Erin E. Michalak  
Index  
[More information](#)

Index

- valproate 113, 134  
    and antimanic treatment 17  
    and BD type I depression treatment 25  
    for late-life BD treatment 88  
vascular depression 87  
vascular mania 87  
waist:hip ratio 114
- weight gain 18, 19, 42, 77–9, 88, 89, 99, 106, 108–11, 114, 125, 146, 170  
white matter hyperintensities (WMHs) 86, 87, 194  
white matter lesions 86, 196  
WMHs *see* white matter hyperintensities (WMHs)  
World Health Organization (WHO) 9, 106, 123, 163, 176
- years lost to disability (YLD) 199  
Young mania rating scale (YMRS) 50, 78, 188  
ziprasidone 13, 15, 41, 75, 79, 109, 110, 114, 115  
    for antimanic treatment 19, 35  
zonisamide 13  
    for antimanic treatment 17